Osteoprotegerin is associated with cardiovascular risk in hypertension and/or diabetes

A New Equation to Estimate Glomerular Filtration Rate

(2013) Andrew S. Levey et al.   ANNALS OF INTERNAL MEDICINE

Increased plasma soluble endoglin levels as an indicator of cardiovascular alterations in hypertensive and diabetic patients

(2011) Ana M Blázquez-Medela et al.   BMC Medicine

Association of Osteoprotegerin With Aortic Stiffness in Patients With Symptomatic Peripheral Artery Disease and in Healthy Subjects

(2010) M. Zagura et al.   AMERICAN JOURNAL OF HYPERTENSION

Association of Serum Osteoprotegerin With Left Ventricular Mass in African American Adults With Hypertension

(2010) A. Noheria et al.   AMERICAN JOURNAL OF HYPERTENSION

Osteoprotegerin as a Predictor of Coronary Artery Disease and Cardiovascular Mortality and Morbidity

(2010) Shreenidhi M. Venuraju et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Endothelial Dysfunction as a Target for Prevention of Cardiovascular Disease

(2009) D. Versari et al.   DIABETES CARE

A catalogue of reporting guidelines for health research

(2009) I. Simera et al.   EUROPEAN JOURNAL OF CLINICAL INVESTIGATION

Osteoprotegerin in relation to type 2 diabetes mellitus and the metabolic syndrome in postmenopausal women

(2009) Iraj Nabipour et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Endothelial Dysfunction in Diabetes: From Mechanisms to Therapeutic Targets

(2008) Maria Potenza et al.   CURRENT MEDICINAL CHEMISTRY

Relationship of elevated osteoprotegerin with insulin resistance, CRP, and TNF-α levels in men with type 2 diabetes

(2008) Subhashini Yaturu et al.   CYTOKINE

Plasma osteoprotegerin levels predict cardiovascular and all-cause mortality and deterioration of kidney function in type 1 diabetic patients with nephropathy

(2008) A. Jorsal et al.   DIABETOLOGIA

Plasma Osteoprotegerin Concentrations in Type 2 Diabetic Patients and its Association with Neuropathy

(2008) H. Terekeci et al.   EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES